Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311494591> ?p ?o ?g. }
- W4311494591 endingPage "6150" @default.
- W4311494591 startingPage "6150" @default.
- W4311494591 abstract "Immune checkpoint blockade (ICB) is now standard of care for several metastatic epithelial cancers and prolongs life expectancy for a significant fraction of patients. A hostile tumor microenvironment (TME) induced by intrinsic oncogenic signaling induces an immunosuppressive niche that protects the tumor cells, limiting the durability and efficacy of ICB therapies. Addition of receptor tyrosine kinase inhibitors (RTKi) as potential modulators of an unfavorable local immune environment has resulted in moderate life expectancy improvement. Though the combination strategy of ICB and RTKi has shown significantly better results compared to individual treatment, the benefits and adverse events are additive whereas synergy of benefit would be preferable. There is therefore a need to investigate the potential of inhibitors other than RTKs to reduce malignant cell survival while enhancing anti-tumor immunity. In the last five years, preclinical studies have focused on using small molecule inhibitors targeting cell cycle and DNA damage regulators such as CDK4/6, CHK1 and poly ADP ribosyl polymerase (PARP) to selectively kill tumor cells and enhance cytotoxic immune responses. This review provides a comprehensive overview of the available drugs that attenuate immunosuppression and overcome hostile TME that could be used to boost FDA-approved ICB efficacy in the near future." @default.
- W4311494591 created "2022-12-26" @default.
- W4311494591 creator A5011676191 @default.
- W4311494591 creator A5038559109 @default.
- W4311494591 creator A5048082417 @default.
- W4311494591 creator A5056972434 @default.
- W4311494591 creator A5068439065 @default.
- W4311494591 creator A5074507203 @default.
- W4311494591 creator A5085415276 @default.
- W4311494591 date "2022-12-13" @default.
- W4311494591 modified "2023-10-01" @default.
- W4311494591 title "Repurposing of Commercially Existing Molecular Target Therapies to Boost the Clinical Efficacy of Immune Checkpoint Blockade" @default.
- W4311494591 cites W1498931318 @default.
- W4311494591 cites W1529178741 @default.
- W4311494591 cites W1788204179 @default.
- W4311494591 cites W1897605380 @default.
- W4311494591 cites W1979811833 @default.
- W4311494591 cites W1987165863 @default.
- W4311494591 cites W1996793882 @default.
- W4311494591 cites W1999539710 @default.
- W4311494591 cites W2011458181 @default.
- W4311494591 cites W2028433016 @default.
- W4311494591 cites W2029399624 @default.
- W4311494591 cites W2034751554 @default.
- W4311494591 cites W2052874737 @default.
- W4311494591 cites W2054344840 @default.
- W4311494591 cites W2066671159 @default.
- W4311494591 cites W2083158919 @default.
- W4311494591 cites W2089714303 @default.
- W4311494591 cites W2099044540 @default.
- W4311494591 cites W2106190040 @default.
- W4311494591 cites W2106777138 @default.
- W4311494591 cites W2106910596 @default.
- W4311494591 cites W2111381709 @default.
- W4311494591 cites W2112100378 @default.
- W4311494591 cites W2116376943 @default.
- W4311494591 cites W2120572492 @default.
- W4311494591 cites W2121626779 @default.
- W4311494591 cites W2126216098 @default.
- W4311494591 cites W2128339707 @default.
- W4311494591 cites W2138617860 @default.
- W4311494591 cites W2146810078 @default.
- W4311494591 cites W2155364136 @default.
- W4311494591 cites W2163264180 @default.
- W4311494591 cites W2173550086 @default.
- W4311494591 cites W2198986768 @default.
- W4311494591 cites W2272817250 @default.
- W4311494591 cites W2292383635 @default.
- W4311494591 cites W2312199902 @default.
- W4311494591 cites W2314057593 @default.
- W4311494591 cites W2320177900 @default.
- W4311494591 cites W2329348377 @default.
- W4311494591 cites W2339723519 @default.
- W4311494591 cites W2340861895 @default.
- W4311494591 cites W2359306646 @default.
- W4311494591 cites W2400514548 @default.
- W4311494591 cites W2480201404 @default.
- W4311494591 cites W2520148131 @default.
- W4311494591 cites W2531934133 @default.
- W4311494591 cites W2539792908 @default.
- W4311494591 cites W2544675721 @default.
- W4311494591 cites W2560367415 @default.
- W4311494591 cites W2584088501 @default.
- W4311494591 cites W2587048937 @default.
- W4311494591 cites W2590229508 @default.
- W4311494591 cites W2593768764 @default.
- W4311494591 cites W2597062310 @default.
- W4311494591 cites W2605738899 @default.
- W4311494591 cites W2626412976 @default.
- W4311494591 cites W2750328162 @default.
- W4311494591 cites W2753432434 @default.
- W4311494591 cites W2753529762 @default.
- W4311494591 cites W2758375389 @default.
- W4311494591 cites W2763164439 @default.
- W4311494591 cites W2765367127 @default.
- W4311494591 cites W2766016994 @default.
- W4311494591 cites W2767867309 @default.
- W4311494591 cites W2768434280 @default.
- W4311494591 cites W2769376007 @default.
- W4311494591 cites W2774875527 @default.
- W4311494591 cites W2775503072 @default.
- W4311494591 cites W2785594347 @default.
- W4311494591 cites W2789574985 @default.
- W4311494591 cites W2795875233 @default.
- W4311494591 cites W2801309958 @default.
- W4311494591 cites W2802480234 @default.
- W4311494591 cites W2804340288 @default.
- W4311494591 cites W2805250652 @default.
- W4311494591 cites W2806614796 @default.
- W4311494591 cites W2807942883 @default.
- W4311494591 cites W2808497725 @default.
- W4311494591 cites W2808790891 @default.
- W4311494591 cites W2811281203 @default.
- W4311494591 cites W2884280196 @default.
- W4311494591 cites W2891878264 @default.
- W4311494591 cites W2892170438 @default.
- W4311494591 cites W2895951641 @default.
- W4311494591 cites W2902609075 @default.